NCT04513951View on ClinicalTrials.gov

AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 1, 2020

Primary Completion Date

June 28, 2023

Study Completion Date

December 31, 2024

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG

5Fluorouracil

phase II

DRUG

L-leucovorin

phase II

DRUG

Irinotecan

phase II

DRUG

Oxaliplatin

phase II

DRUG

Cetuximab

phase II

DRUG

Avelumab

phase II

Trial Locations (1)

56126

U.O. Oncologia Medica 2 Universitaria - Azienda Ospedaliero-Universitaria Pisana Dipartimento di Ricerca Traslazionale e Nuove Tecnologie - University of Pisa, Pisa

All Listed Sponsors

lead

Gruppo Oncologico del Nord-Ovest

OTHER

NCT04513951 - AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients | Biotech Hunter | Biotech Hunter